DE102004059674A1 - Transdermal delivery system to treat movement disease and post-operative illness comprises scopolamine and a matrix comprising styrene-butadiene-copolymer-bonding adhesive - Google Patents

Transdermal delivery system to treat movement disease and post-operative illness comprises scopolamine and a matrix comprising styrene-butadiene-copolymer-bonding adhesive Download PDF

Info

Publication number
DE102004059674A1
DE102004059674A1 DE102004059674A DE102004059674A DE102004059674A1 DE 102004059674 A1 DE102004059674 A1 DE 102004059674A1 DE 102004059674 A DE102004059674 A DE 102004059674A DE 102004059674 A DE102004059674 A DE 102004059674A DE 102004059674 A1 DE102004059674 A1 DE 102004059674A1
Authority
DE
Germany
Prior art keywords
delivery system
transdermal delivery
matrix
scopolamine
styrene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE102004059674A
Other languages
German (de)
Other versions
DE102004059674B4 (en
Inventor
Elisabeth Meyer
Sarah Mcleod
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Luye Pharma AG
Original Assignee
Novosis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novosis AG filed Critical Novosis AG
Priority to DE102004059674A priority Critical patent/DE102004059674B4/en
Publication of DE102004059674A1 publication Critical patent/DE102004059674A1/en
Application granted granted Critical
Publication of DE102004059674B4 publication Critical patent/DE102004059674B4/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Transdermal delivery system (A) comprises scopolamine (I) as active substance and a matrix (II) comprising styrol-butadiene-copolymer-bonding adhesive. ACTIVITY : None given. MECHANISM OF ACTION : None given.

Description

Bereits auf dem Markt befindliche Scopolamin-TDS, wie z.B. Transderm Scop®, weisen relativ komplizierte Zusammensetzungen auf. US-Patent 4,031,894 [2] beschreibt ein Pflaster mit vier unterschiedlichen Schichten, eine Trägerfolie, eine gelierte Mineralöl-Polyisobuten-Scopolamin Reservoirschicht, eine mikroporöse Membran und schließlich eine gelierte Mineralöl-Polyisobutan-Scopolamin Klebeschicht. Wie in den folgenden Patenten EP 0 863 751 [3], US 6, 238, 700 [4] und US 6, 569, 448 [5] beschrieben, wurde nach einigen Jahren der Herstellung festgestellt, dass die Kristallisation des Produkts eine signifikant nachteilige Wirkung auf die Abgabe des Scopolamins hervorbrachte, wobei eine Lösung dieses Problems in den zuvor erwähnten Patenten beschrieben ist und das Tempern (Erhitzen auf eine Temperatur über den Schmelzpunkt der Kristalle, dann Abkühlen auf Umgebungstemperatur) jedes einzelnen Scopolamin enthaltenden Films und Laminats erfordert, wodurch der Herstellungsprozess verkompliziert wird, was zu höheren Produktionskosten führen kann.Already on the market scopolamine TDS, such as Transderm Scop ® , have relatively complicated compositions. U.S. Patent 4,031,894 [2] describes a patch having four distinct layers, a carrier sheet, a gelled mineral oil-polyisobutene-scopolamine reservoir layer, a microporous membrane, and finally a gelled mineral oil-polyisobutane scopolamine adhesive layer. As in the following patents EP 0 863 751 [3] US 6, 238, 700 [4] and US Pat. No. 6,569,448 [5], after a few years of manufacture, it was found that crystallization of the product produced a significant adverse effect on scopolamine release, a solution to this problem being described in the aforementioned patents and tempering (heating to a temperature above about 10%) the melting point of the crystals, then cooling to ambient temperature) of each individual scopolamine-containing film and laminate, thereby complicating the manufacturing process, which can lead to higher production costs.

Transderm Scop®, wie in US-Patent 4,904,475 [6] beschrieben, besteht aus 4 Schichten, einer Trägerfolie, einem Arzneimittelreservoir, einer die Geschwindigkeit kontrollierenden Membran und einem Kontaktkleber. Dies ist ein verhältnismäßig komplizierter Aufbau und deshalb werden die Herstellungskosten deutlich höher sein, da der Herstellungsprozess komplexer sein wird und länger zur Fertigstellung braucht. Ein weiterer Nachteil des Transderm Scop® TDS ist der kalte Fluss, der zur Verunreinigung der Kleidung oder Hände mit der "toxischen" Substanz während des Anbringens und/oder Tragens des TDS führt.Transderm Scop described ®, as described in U.S. Patent 4,904,475 [6], consists of 4 layers, a backing film, a drug reservoir, a rate controlling membrane and a contact adhesive. This is a relatively complicated construction and therefore the manufacturing cost will be significantly higher as the manufacturing process will be more complex and take longer to complete. Another disadvantage of the Transderm Scop ® TDS is the cold flow, which leads to contamination of clothing or hands with the "toxic" substance during the attachment and / or wearing of the TDS.

Die Erfindung betrifft ein transdermales Abgabesystem, umfassend Scopolamin als Wirkstoff und eine Matrix, umfassend einen Styrol-Butadien-Copolymer Haftkleber.The The invention relates to a transdermal delivery system comprising scopolamine as an active ingredient and a matrix comprising a styrene-butadiene copolymer Pressure sensitive adhesive.

Die Matrix des transdermalen Abgabesystems kann einen Styrol-Butadien-Styrol-Blockcopolymer Haftkleber umfassen.The Matrix of the transdermal delivery system may be a styrene-butadiene-styrene block copolymer Include pressure-sensitive adhesive.

Des Weiteren kann das transdermale Abgabesystem eine Trägerfolie, die Matrix und eine Schutzdecklage umfassen und keine die Geschwindigkeit kontrollierende Membran.Of Furthermore, the transdermal delivery system may include a carrier foil, the matrix and a protective cover layer and not the speed controlling membrane.

Des Weiteren kann das transdermale Abgabesystem eine Trägerfolie, die Matrix und eine Schutdecklage und eine die Geschwindigkeit kontrollierende Membran umfassen.Of Furthermore, the transdermal delivery system may include a carrier foil, the matrix and a protective layer and a speed controlling Membrane include.

Des Weiteren kann die Matrix des transdermalen Abgabesystems einen Permeationsförderer umfassen, vorzugsweise einen Permeationsförderer ausgewählt aus der Gruppe, bestehend aus

  • – Ethanol,
  • – Aloe Vera,
  • – Labrafil,
  • – Cremophor,
  • – Polyethylenglycol und dessen Derivate,
  • – Löslichmacher Gamma,
  • – Glycerol,
  • – Stearin,
  • – Tocopherol (Vitamin E),
  • – Macrogol,
  • – Oleyloleat,
  • – Pluronic,
  • – Polyoxyethylensorbitanester,
  • – Cholsäureester,
  • – Benzalkoniumchlorid,
  • – Capryl/Caprin-Triglyceride,
  • – Dodecanol,
  • – Natriumstearat,
  • – Myristylmyristinsäureester,
  • – Linolensäure,
  • – Mineralöl,
  • – Crovol,
  • – Carbopol,
  • – Controx,
  • – Olivenöl,
  • – Texapon,
  • – Cetiol,
  • – Labrasol,
  • – Octyldodecyllactat,
  • – Softcutol und
  • – Tween
und insbesondere Ölsäure als Permeationsförderer.Furthermore, the matrix of the transdermal delivery system may comprise a permeation enhancer, preferably a permeation enhancer selected from the group consisting of
  • Ethanol,
  • - aloe vera,
  • - Labrafil,
  • - Cremophor,
  • Polyethylene glycol and its derivatives,
  • Solubilizer gamma,
  • - glycerol,
  • - stearin,
  • - tocopherol (vitamin E),
  • - Macrogol,
  • Oleyl oleate,
  • - Pluronic,
  • - polyoxyethylene sorbitan ester,
  • - cholic acid ester,
  • - benzalkonium chloride,
  • Caprylic / capric triglycerides,
  • - dodecanol,
  • Sodium stearate,
  • Myristyl myristic acid ester,
  • - linolenic acid,
  • - mineral oil,
  • - Crovol,
  • - Carbopol,
  • - Controx,
  • - olive oil,
  • - Texapon,
  • - Cetiol,
  • - Labrasol,
  • Octyldodecyl lactate,
  • - Softcutol and
  • - Tween
and especially oleic acid as a permeation enhancer.

Des Weiteren kann, was das transdermale Abgabesystem betrifft, der Scopolamingehalt 5 bis 15 und insbesondere etwa 10 Gew.% sein, basierend auf der Matrix.Of Further, as far as the transdermal delivery system is concerned, the level of scopolamine may be 5 to 15 and especially about 10 wt.% Be based on the Matrix.

Des Weiteren kann, was das transdermale Abgabesystem betrifft, der Scopolamingehalt einer Abgabe von 500 μg bis 2 mg und insbesondere etwa 1 mg über mindestens bis zu 72 h entsprechen.Of Further, as far as the transdermal delivery system is concerned, the level of scopolamine may be a delivery of 500 μg to 2 mg and especially about 1 mg for at least up to 72 h correspond.

Des Weiteren kann, was das transdermale Abgabesystem betrifft, der Scopolamingehalt einer Abgabe entsprechen, die einem Blutspiegel von etwa 87 pg/ml über mindestens bis zu 72 h entspricht.Of Further, as far as the transdermal delivery system is concerned, the level of scopolamine may be corresponding to a blood level of about 87 pg / ml over at least up to 72 h.

Des Weiteren kann das transdermale Abgabesystem ein kreisförmiges, ovales, rechteckiges oder quadratisches Matrixpflaster sein.Of Further, the transdermal delivery system may be a circular, oval, rectangular or square matrix plaster.

Des Weiteren kann das transdermale Abgabesystem eine Größe von 1,0 bis 3,0 und insbesondere 1,5 bis 2,5 cm2 haben.Furthermore, the transdermal delivery system may have a size of 1.0 to 3.0 and in particular 1.5 to 2.5 cm 2 .

Des Weiteren kann, was das transdermale Abgabesystem betrifft, die Matrix ein Flächengewicht von 40 bis 140, vorzugsweise 80 bis 100, und insbesondere etwa 90 g/m2 haben.Furthermore, as far as the transdermal delivery system is concerned, the matrix may have a basis weight of 40 to 140, preferably 80 to 100, and most preferably about 90 g / m 2 .

Das erfindungsgemäße transdermale Abgabesystem kann für die Behandlung von Bewegungskrankheit bereitgestellt werden.The Transdermal according to the invention Dispensing system can for the treatment of motion sickness will be provided.

Schließlich kann das erfindungsgemäße transdermale Abgabesystem für die Behandlung von postoperativer Übelkeit bereitgestellt werden.Finally, can the transdermal invention Delivery system for the treatment of postoperative nausea will be provided.

Überraschend wurde festgestellt, dass ein linearer Fluss mit den benötigten Spiegeln über 72 Stunden mit a) einem weitaus geringeren Matrixgewicht und b) sogar ohne die Verwendung einer die Geschwindigkeit kontrollierenden Membran erreicht werden konnte. Der Fluss von Scopolamin aus dem hierin beschriebenen Scopolamin-TDS wurde festgestellt, ähnlich zu dem aus Transderm Scop® zu sein (Verweis auf 2 und 3). Mit der Zugabe eines Förderers zu der Aktivmatrix kann der Fluss von Scopolamin über 72 Stunden merklich angetrieben werden, weshalb das Potential für eine Reduktion der Arzneimittelkonzentration oder Größe des Endprodukts gegeben ist; Hautpermeations-Vergleichsdaten von Transderm Scop® und Scopolamin-TDS sind in 3 gezeigt. Der Aufbau des Scopolamin-TDS ist unkompliziert, was zu einer Vereinfachung der Herstellung führt und somit zu einer merklich schnelleren Herstellung mit geringeren Kosten. Das geringe Flächengewicht des TDS bedeutet, dass kalter Fluss überhaupt kein Problem aufwirft.Surprisingly, it was found that a linear flux with the required levels over 72 hours could be achieved with a) a much lower matrix weight and b) even without the use of a rate controlling membrane. The flow of scopolamine from the process described herein scopolamine TDS was found similar to that of Transderm Scop ® (to be reference to 2 and 3 ). With the addition of a promoter to the active matrix, the flow of scopolamine can be markedly driven for 72 hours, thus giving the potential for a reduction in the drug concentration or size of the final product; Skin permeation data from Transderm Scop ® and scopolamine TDS are available in 3 shown. The structure of the scopolamine TDS is straightforward, which leads to a simplification of the production and thus to a noticeably faster production with lower costs. The low basis weight of the TDS means that cold flow poses no problem whatsoever.

1. – Seitenansicht von Scopolamin-TDS 1 , - Side view of scopolamine TDS

2. – Hauptpermeation des entwickelten Scopolamin-TDS 2 , - Main permeation of the developed scopolamine TDS

3. – Vergleich der Hautpermeationen: Transderm Scop® mit dem entwickelten Scopolamin-TDS 3 , - Comparison of skin permeation: Transderm Scop ® with the developed scopolamine TDS

Ein transdermales Abgabesystem (TDS) für Scopolamin wurde für die Behandlung von Bewegungskrankheit entwickelt. Das Abgabeziel für Scopolamin ist annähernd 1 mg über 72 Stunden, um Blutspiegel von annähernd 87 pg/ml zu ergeben.One transdermal delivery system (TDS) for scopolamine was used for the treatment developed from motion sickness. The delivery target for scopolamine is approximate 1 mg over 72 hours to give blood levels of approximately 87 pg / ml.

Das Scopolamin-TDS besteht aus einem kreisförmigen Matrixpflaster mit einer Fläche von 1,5 bis 2,5 cm2 und einem Flächengewicht von etwa 90 g/m2, die Aktivmatrix enthält einen Styrol-Butadien-Styrol-Copolymer Haftkleber (PSA) (DT-6173) mit 10 % Scopolamin. Verweis auf 1.

  • 1. Fachinformation, Scopoderm TTS®, Novartis Consumer Health GmbH, 2003.
  • 2. J. E. Shaw, J. Urquhart & S. K. Chandrasekaran: Verband zur transdermalen Verabreichung von Scopolamin, um Übelkeit zu verhindern, US-Patent 4,031,894.
  • 3. J. W. Dohner & S. A. Bura: Verbessertes Verfahren zur Verhinderung der Kristallbildung in einer Dispersion einer Flüssigkeit in einer Matrix, EP-Patent 0 863 751.
  • 4. J. W. Dohner, S. A. Bura & R. E. Ford: Verfahren zur Verhinderung der Kristallbildung in einer Dispersion einer Flüssigkeit in einer Matrix, US-Patent 6,238,700, 1998 5. J. W. Dohner, S.A. Bura & R. E. Ford: Verfahren zur Verhinderung der Kristallbildung in einer Dispersion einer Flüssigkeit in einer Matrix, US-Patent 6,569,448.
  • 6. R. M. Gale & D. J. Enscore: Transdermale Abgabe aus einem wässrigen Reservoir, US-Patent 4,904,475.
The scopolamine TDS consists of a circular matrix patch having an area of 1.5 to 2.5 cm 2 and a basis weight of about 90 g / m 2 , the active matrix containing a styrene-butadiene-styrene copolymer pressure-sensitive adhesive (PSA) (DT -6173) with 10% scopolamine. Reference to 1 ,
  • 1. prescribing information, Scopoderm TTS ®, Novartis Consumer Health GmbH., 2003
  • 2. JE Shaw, J. Urquhart & SK Chandrasekaran: Association for transdermal administration of scopolamine to prevent nausea, U.S. Patent 4,031,894.
  • 3. JW Dohner & SA Bura: Improved method of preventing crystal formation in a dispersion of a liquid in a matrix, EP patent 0 863 751.
  • 4. JW Dohner, SA Bura & RE Ford: Method for Preventing Crystal Formation in a Dispersion of a Liquid in a Matrix, US Pat. No. 6,238,700, 1998. 5. JW Dohner, SA Bura & RE Ford: Method of Preventing Crystal Formation in a Dispersion a liquid in a matrix, U.S. Patent 6,569,448.
  • 6. RM Gale & DJ Enscore: Transdermal Delivery from an Aqueous Reservoir, U.S. Patent 4,904,475.

Claims (13)

Transdermales Abgabesystem, umfassend Scopolamin als Wirkstoff und eine Matrix, umfassend einen Styrol-Butadien-Copolymer-Haftkleber.Transdermal delivery system comprising scopolamine as active ingredient and a matrix comprising a styrene-butadiene copolymer pressure-sensitive adhesive. Transdermales Abgabesystem gemäß Anspruch 1, wobei die Matrix einen Styrol-Butadien-Styrol-Blockcopolymer-Haftkleber umfasst.Transdermal delivery system according to claim 1, wherein the matrix a styrene-butadiene-styrene block copolymer pressure-sensitive adhesive. Transdermales Abgabesystem gemäß Anspruch 1 und/oder 2, wobei das System eine Trägerfolie, die Matrix und eine Schutzdecklage umfasst und keine die Geschwindigkeit kontrollierende Membran.Transdermal delivery system according to claim 1 and / or 2, wherein the system a carrier foil, the matrix and a protective cover layer includes and not the speed controlling membrane. Transdermales Abgabesystem gemäß Anspruch 1 und/oder 2, wobei das System eine Trägerfolie, die Matrix und eine Schutzdecklage und eine die Geschwindigkeit kontrollierende Membran umfasst.Transdermal delivery system according to claim 1 and / or 2, wherein the system a carrier foil, the matrix and a protective top layer and a speed comprising controlling membrane. Transdermales Abgabesystem gemäß mindestens einem der vorhergehenden Ansprüche, wobei die Matrix einen Permeationsförderer umfasst, und insbesondere Ölsäure als Permeationsförderer.Transdermal delivery system according to at least one of the preceding Claims, the matrix comprising a permeation enhancer, and in particular oleic acid Permeation. Transdermales Abgabesystem gemäß mindestens einem der vorhergehenden Ansprüche, wobei der Scopolamingehalt 5 bis 15 und insbesondere etwa 10 Gew.% beträgt, basierend auf der Matrix.Transdermal delivery system according to at least one of the preceding Claims, the scopolamine content being from 5 to 15 and especially about 10% by weight is, based on the matrix. Transdermales Abgabesystem gemäß mindestens einem der vorhergehenden Ansprüche, wobei der Scopolamingehalt einer Abgabe von 500 μm bis 2 mg und insbesondere etwa 1 mg über mindestens bis zu 72 h entspricht.Transdermal delivery system according to at least one of the preceding Claims, wherein the scopolamine content of a donation of 500 .mu.m to 2 mg and in particular about 1 mg over at least up to 72 hours. Transdermales Abgabesystem gemäß mindestens einem der vorhergehenden Ansprüche, wobei der Scopolamingehalt einer Abgabe entspricht, die einem Blutspiegel von etwa 87 pg/ml über mindestens bis zu 72 h entspricht.Transdermal delivery system according to at least one of the preceding claims, wherein the scopolamine content corresponds to a delivery, which corresponds to a blood level of about 87 pg / ml for at least up to 72 h. Transdermales Abgabesystem gemäß mindestens einem der vorhergehenden Ansprüche, wobei das System ein kreisförmiges, ovales, rechteckiges oder quadratisches Matrixpflaster ist.Transdermal delivery system according to at least one of the preceding Claims, the system being a circular, oval, rectangular or square matrix plaster is. Transdermales Abgabesystem gemäß mindestens einem der vorhergehenden Ansprüche, wobei das transdermale Abgabesystem eine Größe von 1,0 bis 3,0 und insbesondere 1,5 bis 2,5 cm2 hat.A transdermal delivery system according to any one of the preceding claims, wherein the transdermal delivery system has a size of 1.0 to 3.0 and in particular 1.5 to 2.5 cm 2 . Transdermales Abgabesystem gemäß mindestens einem der vorhergehenden Ansprüche, wobei die Matrix ein Flächengewicht von 40 bis 140, vorzugsweise 80 bis 100, und insbesondere etwa 90 g/m2 hat.Transdermal delivery system according to at least one of the preceding claims, wherein the matrix has a basis weight of 40 to 140, preferably 80 to 100, and in particular about 90 g / m 2 . Transdermales Abgabesystem gemäß mindestens einem der vorhergehenden Ansprüche für die Behandlung von Bewegungskrankheit.Transdermal delivery system according to at least one of the preceding claims for the Treatment of motion sickness. Transdermales Abgabesystem gemäß mindestens einem der Ansprüche 1 bis 11 für die Behandlung von postoperativer Übelkeit.Transdermal delivery system according to at least one of claims 1 to 11 for the treatment of postoperative nausea.
DE102004059674A 2004-12-10 2004-12-10 Transdermal delivery system for scopolamine Active DE102004059674B4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE102004059674A DE102004059674B4 (en) 2004-12-10 2004-12-10 Transdermal delivery system for scopolamine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004059674A DE102004059674B4 (en) 2004-12-10 2004-12-10 Transdermal delivery system for scopolamine

Publications (2)

Publication Number Publication Date
DE102004059674A1 true DE102004059674A1 (en) 2006-06-14
DE102004059674B4 DE102004059674B4 (en) 2010-05-06

Family

ID=36500210

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102004059674A Active DE102004059674B4 (en) 2004-12-10 2004-12-10 Transdermal delivery system for scopolamine

Country Status (1)

Country Link
DE (1) DE102004059674B4 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2667861A2 (en) * 2011-01-26 2013-12-04 CSI GmbH Extended-release beta agonist/anticholinergic transdermal patches and methods for using the same

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102018118507A1 (en) 2018-07-31 2020-02-06 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system for the delivery of scopolamine without a membrane

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904475A (en) * 1985-05-03 1990-02-27 Alza Corporation Transdermal delivery of drugs from an aqueous reservoir
EP0356382A2 (en) * 1988-08-02 1990-02-28 Ciba-Geigy Ag Multilayer plaster
DE3910543A1 (en) * 1989-04-01 1990-10-11 Lohmann Therapie Syst Lts TRANSDERMAL THERAPEUTIC SYSTEM WITH INCREASED ACTIVE FLUID AND METHOD FOR THE PRODUCTION THEREOF
DE19825499A1 (en) * 1998-06-08 1999-12-09 Beiersdorf Ag Patches containing active ingredient
US20010006628A1 (en) * 1997-06-26 2001-07-05 Govil Sharad K. Adhesive mixture for transdermal delivery of highly plasticizing drugs
DE69622780T2 (en) * 1995-04-28 2003-04-03 Lead Chem Co Ltd Transdermal therapeutic system with controlled drug release
WO2004098472A1 (en) * 2002-08-30 2004-11-18 Watson Pharmaceuticals, Inc. Transdermal delivery systems and methods

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5325000A (en) * 1999-06-05 2000-12-28 David Houze Solubility enhancement of drugs in transdermal drug delivery systems and methodsof use

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904475A (en) * 1985-05-03 1990-02-27 Alza Corporation Transdermal delivery of drugs from an aqueous reservoir
EP0356382A2 (en) * 1988-08-02 1990-02-28 Ciba-Geigy Ag Multilayer plaster
DE3910543A1 (en) * 1989-04-01 1990-10-11 Lohmann Therapie Syst Lts TRANSDERMAL THERAPEUTIC SYSTEM WITH INCREASED ACTIVE FLUID AND METHOD FOR THE PRODUCTION THEREOF
DE69622780T2 (en) * 1995-04-28 2003-04-03 Lead Chem Co Ltd Transdermal therapeutic system with controlled drug release
US20010006628A1 (en) * 1997-06-26 2001-07-05 Govil Sharad K. Adhesive mixture for transdermal delivery of highly plasticizing drugs
DE19825499A1 (en) * 1998-06-08 1999-12-09 Beiersdorf Ag Patches containing active ingredient
WO2004098472A1 (en) * 2002-08-30 2004-11-18 Watson Pharmaceuticals, Inc. Transdermal delivery systems and methods

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2667861A2 (en) * 2011-01-26 2013-12-04 CSI GmbH Extended-release beta agonist/anticholinergic transdermal patches and methods for using the same
EP2667861A4 (en) * 2011-01-26 2014-07-16 Csi Gmbh Extended-release beta agonist/anticholinergic transdermal patches and methods for using the same

Also Published As

Publication number Publication date
DE102004059674B4 (en) 2010-05-06

Similar Documents

Publication Publication Date Title
DE19814084B4 (en) D2 agonist-containing transdermal therapeutic system for the treatment of Parkinson's syndrome and process for its preparation
EP2094249B1 (en) Transdermal therapeutic system for administering the active substance buprenorphine
DE60304477T2 (en) IMPROVED TRANSDERMAL DISTRIBUTION SYSTEM FOR THE ADMINISTRATION OF ROTIGOTIN
DE10141651B4 (en) Transdermal Therapeutic System (TTS) with the active ingredient Fentanyl and process for its preparation
DE60314298T2 (en) THERAPEUTIC PLASTER WITH CAPSAICIN-CONTAINING POLYSILOXAN MATRIX
EP2468274B1 (en) Transdermal therapeutic system for application of an agent
EP0617623B1 (en) Transdermally administered system containing acetylsalicylic acid for thrombosis therapy
EP2295046B1 (en) Transdermal therapeutic system for application of fentanyl or an analogue material thereof
DE112014002664T5 (en) Transdermal delivery system
DE102007021549A1 (en) Transdermal therapeutic system containing at least two opioids
EP2111857A1 (en) Transdermal therapeutic system for application of fentanyl or an analogue material thereof
WO1994016707A1 (en) Transdermal therapeutic system with galanthamine as active ingredient
DE19814087A1 (en) Moisture-activated therapeutic system
CA2762770A1 (en) Surface active agent compositions and methods for enhancing oxygenation, reducing bacteria and improving wound healing
DE4342174C1 (en) Transdermal therapeutic system and a method for producing a transdermal therapeutic system for the combined transdermal application of physostigmine and scopolamine for the prophylaxis and pretreatment of poisoning by highly toxic organophosphorus neurotoxins, in particular Soman and its use
DE60309329T2 (en) IMPROVED TRANSDERMAL DELIVERY SYSTEM
DE3905051C2 (en)
DE19911262A1 (en) Device for dispensing cosmetic active ingredients
DE102004059674A1 (en) Transdermal delivery system to treat movement disease and post-operative illness comprises scopolamine and a matrix comprising styrene-butadiene-copolymer-bonding adhesive
DE3319469C2 (en)
EP0668074B1 (en) Transdermal therapeutic system
EP2366388A1 (en) Non-occlusive transdermal therapeutic system for administering buprenorphine
EP0659079B1 (en) Transdermal therapeutic system with pentylene tetrazol as active substance
EP0671916A1 (en) Transdermal administration system containing acetylsalicylic acid for antithrombotic therapy and the prevention of cancer
EP3651744B1 (en) Fampridine tts

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
8127 New person/name/address of the applicant

Owner name: ACINO AG, 83714 MIESBACH, DE

8181 Inventor (new situation)

Inventor name: MCLEOD, SARAH, 81675 MUENCHEN, DE

Inventor name: MEYER, ELISABETH, 83714 MIESBACH, DE

8364 No opposition during term of opposition
R081 Change of applicant/patentee

Owner name: LUYE PHARMA AG, DE

Free format text: FORMER OWNER: ACINO AG, 83714 MIESBACH, DE

R082 Change of representative

Representative=s name: BEETZ & PARTNER MBB PATENTANWAELTE, DE

Representative=s name: BEETZ & PARTNER MBB PATENT- UND RECHTSANWAELTE, DE